The purpose of this study is to assess the safety, tolerability, and immunogenicity of
booster dose of vaccine in participants who are generally healthy or with stable pre-existing
health conditions. Study details include:
The study duration per participant will be approximately 209 days (28 days screening, 1
day vaccination, and 180 days follow-up).
The treatment will include 1 booster dose only.
The visit frequency will be 6 on-site visits and 1 phone visit.
This is a Phase II, prospective, randomized, observer-blinded, multi-center study, to
evaluate the safety, tolerability, and immunogenicity of a booster vaccination with AZD1222,
mRNA-1273, or MVC-COV1901 vaccine. Approximately 960 participants aged 18 ~ < 80 years, who
received homologous two doses of vaccines 150 ~ 365 days ago, will be enrolled and divided
into three groups. Each group will consist of 320 eligible subjects, and for each group the
randomization will be stratified according to study site and age to four treatments (AZD1222,
half dose of mRNA-1273, full dose or half dose of MVC-COV1901 in 1:1:1:1 ratio). Therefore,
within a group, for either age stratum, there will be at least 30 participants for each
Half dose of MVC-COV1901,
Full dose of MVC-COV1901,
Half dose of mRNA-1273
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.